Coherus Oncology, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CHRS research report →
Companywww.coherus.com
Coherus Oncology, Inc. , a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27.
- CEO
- Dennis Lanfear
- IPO
- 2014
- Employees
- 228
- HQ
- Redwood City, CA, US
Price Chart
Valuation
- Market Cap
- $184.84M
- P/E
- -1.36
- P/S
- 3.94
- P/B
- 2.62
- EV/EBITDA
- -0.75
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 60.04%
- Op Margin
- -362.07%
- Net Margin
- -323.49%
- ROE
- -174.71%
- ROIC
- -125.19%
Growth & Income
- Revenue
- $42.17M · -84.20%
- Net Income
- $-170,291,000 · -697.37%
- EPS
- $-1.45 · -680.00%
- Op Income
- $-179,534,000
- FCF YoY
- -577.66%
Performance & Tape
- 52W High
- $2.62
- 52W Low
- $0.71
- 50D MA
- $1.73
- 200D MA
- $1.56
- Beta
- 1.02
- Avg Volume
- 1.29M
Get TickerSpark's AI analysis on CHRS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 23, 26 | Lanfear Dennis M | other | 375,000 |
| Jan 23, 26 | Lanfear Dennis M | other | 750,000 |
| Jan 22, 26 | McMichael Bryan J | other | 225,000 |
| Jan 22, 26 | McMichael Bryan J | other | 112,500 |
| Jan 20, 26 | McMichael Bryan J | other | 1,715 |
| Jan 20, 26 | Lanfear Dennis M | other | 11,839 |
| Jun 12, 25 | O'Donnell-Tormey Jill | other | 112,000 |
| Jun 12, 25 | Newcomer Lee Nisley | other | 112,000 |
| Jun 12, 25 | Wahlstrom Mats | other | 112,000 |
| Jun 12, 25 | Ryan Michael Lee | other | 112,000 |
Our CHRS Coverage
We haven't published any research on CHRS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CHRS Report →